financetom
Business
financetom
/
Business
/
Snowflake Faces Competitive Pressures Despite Q2 Gains, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Snowflake Faces Competitive Pressures Despite Q2 Gains, Oppenheimer Says
Aug 22, 2024 10:18 PM

11:32 AM EDT, 08/22/2024 (MT Newswires) -- Snowflake (SNOW) posed strong product revenue growth in fiscal Q2 due to "stable demand and improving large customer consumption," Oppenheimer said Wednesday in a report.

Investor concerns about competition and Snowflake's ability to execute in artificial intelligence are likely to persist with revenue upside smaller than the previous quarter, Oppenheimer said.

Increased compute revenue from Iceberg adoption, growing traction for products such as Cortex and Snowpark, improving execution and closing rates and leadership in serving analytical workloads are expected to contribute to an improved growth outlook in fiscal 2026, the report said.

Snowflake faces challenges from declining net revenue retention and margin pressures from graphics processing units and AI investments, while potential headwinds from the availability of Iceberg Tables affect product revenue growth, the report said.

Oppenheimer reiterated its outperform rating on Snowflake's stock and kept the price target at $180.

On Wednesday, the company projected fiscal Q3 revenue of $850 million to $855 million. Analysts polled by Capital IQ expect $898.6 million.

Shares of Snowflake fell 13% in recent trading Thursday.

Price: 117.54, Change: -17.52, Percent Change: -12.97

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
Jun 18, 2024
Tuesday, XBiotech Inc ( XBIT )  announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer. The study examined the Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV)), which is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less-than-ideal survival outcomes. Natrunix...
Market Chatter: Ford Plans More Job Cuts in Europe, German Works Council Says
Market Chatter: Ford Plans More Job Cuts in Europe, German Works Council Says
Jun 18, 2024
12:56 PM EDT, 06/18/2024 (MT Newswires) -- Ford Motor ( F ) is planning to make further job cuts in Germany, Spain and the UK, Reuters reported Tuesday, citing Benjamin Gruschka, the head of the works council at Ford's Cologne plant. The number of additional job cuts in Germany is unclear, though a decision is expected by the end of...
Nvidia becomes world's most valuable company
Nvidia becomes world's most valuable company
Jun 18, 2024
(Reuters) -Nvidia ( NVDA ) became the world's most valuable company on Tuesday, dethroning tech heavyweight Microsoft ( MSFT ), as its chips continue to play a central role in a race to dominate the market for artificial intelligence. Shares of the chipmaker climbed 3.2% to $135.21, lifting its market capitalization to $3.326 trillion, just days after overtaking iPhone maker...
UBS CEO pushes back against Swiss critics of bank's size
UBS CEO pushes back against Swiss critics of bank's size
Jun 18, 2024
LUCERNE, Switzerland, June 18 (Reuters) - UBS's CEO on Tuesday hit out at suggestions Switzerland should set tougher regulations for the bank after its 2023 takeover of Credit Suisse, saying fear and populist critics were doing down the business and the country's own prospects. Speaking as the government and regulators mull plans to make the bank hold more capital, UBS...
Copyright 2023-2026 - www.financetom.com All Rights Reserved